Publication November 12, 2026

Triptorelin Featured in New Publication on STEAP2-Targeted PET Probes

A new publication involving triptorelin appeared on November 12, 2026, in the Journal of Medicinal Chemistry. The study is titled "Development and Preclinical Evaluation of Six-Transmembrane Epithelial Antigen of Prostate 2 Targeted PET Probes: A Case of Drug Repurposing Based on Molecular Docking." The publication is listed under PubMed ID 43018598. This work is described as a case of drug repurposing based on molecular docking approaches. No results or findings from the study were included in the available event data. The publication record does not specify outcomes, efficacy data, or safety conclusions related to triptorelin or the STEAP2-targeted PET probes discussed. Triptorelin remains an approved compound, and this publication is noted here solely as a new addition to the scientific literature. Readers interested in the full scope of the research, including methodology and any reported results, should consult the original article directly through the Journal of Medicinal Chemistry. For general background on triptorelin, including its approved uses and regulatory status, readers can refer to the compound overview.

See the full triptorelin overview

Source: https://pubmed.ncbi.nlm.nih.gov/43018598/